Jun He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun He has a total of 358 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoli Xiong
GMU-GIBH Joint School of Life Sciences, Guangdong Provincial Key Laboratory of Protein Modification and Disease, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, China
23 shared publications Zimu Li
Guangzhou National Laboratory
21 shared publicationsBinqian Zou
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
18 shared publicationsBanghui Liu
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
16 shared publicationsJingjing Wang
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
13 shared publications- Ling Chen
Guangzhou National Laboratory
13 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (9) , e3003996
R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation
R1-32-like public antibodies, characterized by shared IGHV1-69/IGLV1-40 usage, are elicited in more than 50% of individuals with COVID-19 and have been implicated in driving recurrent mutations at L452 SARS2 and F490 SARS2 within their convergent epitope in the SARS-CoV-2 spike receptor-binding domain. These mutations effectively mediate escape from non-affinity-matured R1-32-like antibodies with germline-like sequences. Here, we characterize four affinity-matured human R1-32-like antibodies, C092, C807, BD56-104, and BD56-597, that tolerate L452 SARS2 and F490 SARS2 mutations. We show that this tolerance arises from residues introduced by somatic hypermutation at convergent positions across multiple CDR loops and surrounding regions, thereby creating additional contacts that reinforce epitope binding. An unusual N354 SARS2 glycosylation site, which emerged in BA.2.86 and became fixed in its descendants, is linked to escape from affinity-matured R1-32-like antibodies, implying ongoing selection by this public antibody class. Using an AI model trained on extensive neutralization data, we further identified ZL525, an ultrapotent human R1-32-like antibody with pan-SARS-CoV-2 variant activity, including against the highly evasive KP.3 variant carrying the N354 SARS2 glycosylation, and broad sarbecovirus cross-reactivity extending to SARS-CoV-1. Together, these findings show how affinity maturation enables public antibodies to adapt to viral antigenic drift, reveal how public antibody responses contribute to shaping SARS-CoV-2 antigenic evolution, and demonstrate the potential of AI-empowered strategies for discovering broadly neutralizing antibodies.
- 15 September 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (9) , e3003996
Open AccessR1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation
R1-32-like public antibodies, characterized by shared IGHV1-69/IGLV1-40 usage, are elicited in more than 50% of individuals with COVID-19 and have been implicated in driving recurrent mutations at L452 SARS2 and F490 SARS2 within their convergent epitope in the SARS-CoV-2 spike receptor-binding domain. These mutations effectively mediate escape from non-affinity-matured R1-32-like antibodies with germline-like sequences. Here, we characterize four affinity-matured human R1-32-like antibodies, C092, C807, BD56-104, and BD56-597, that tolerate L452 SARS2 and F490 SARS2 mutations. We show that this tolerance arises from residues introduced by somatic hypermutation at convergent positions across multiple CDR loops and surrounding regions, thereby creating additional contacts that reinforce epitope binding. An unusual N354 SARS2 glycosylation site, which emerged in BA.2.86 and became fixed in its descendants, is linked to escape from affinity-matured R1-32-like antibodies, implying ongoing selection by this public antibody class. Using an AI model trained on extensive neutralization data, we further identified ZL525, an ultrapotent human R1-32-like antibody with pan-SARS-CoV-2 variant activity, including against the highly evasive KP.3 variant carrying the N354 SARS2 glycosylation, and broad sarbecovirus cross-reactivity extending to SARS-CoV-1. Together, these findings show how affinity maturation enables public antibodies to adapt to viral antigenic drift, reveal how public antibody responses contribute to shaping SARS-CoV-2 antigenic evolution, and demonstrate the potential of AI-empowered strategies for discovering broadly neutralizing antibodies.
- 13 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) remain lethal malignancies with limited therapeutic options, highlighting an urgent need for more effective treatments. Integrin αvβ6 (ITGB6) is a receptor preferentially expressed in specific types of tumors, such as PDAC and LUAD, and represents a promising yet largely untapped target for cellular immunotherapy. We aimed to develop and preclinically validate a novel chimeric antigen receptor T-cell (CAR-T) therapy targeting ITGB6 for these aggressive solid tumors. A third-generation anti-ITGB6 CAR was designed and constructed, incorporating both CD28 and TLR2 co-stimulatory domains. TLR2 signaling enhances T-cell expansion, cytokine production, and infiltration into solid tumor. The potency and specificity of anti-ITGB6 CAR-T cells were assessed against a panel of ITGB6-positive PDAC and LUAD cell lines, patient-derived organoids (PDOs), orthotopic models, and patient-derived xenograft (PDX) models. Anti-ITGB6 CAR-T cells demonstrated potent cytotoxicity against ITGB6-positive PDAC and LUAD models in vitro, effectively targeting both cell lines and PDOs. In murine xenograft models, a single dose of anti-ITGB6 CAR-T cells induced significant tumor suppression and prolonged survival, with no evidence of on-target/off-tumor toxicity was observed. Our findings provide compelling preclinical proof-of-concept for anti-ITGB6 CAR-T therapy as a potent and safe investigational strategy against ITGB6-positive solid tumors, supporting its clinical translation for patients with PDAC and LUAD.
- 13 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Integrin β6-Targeted CAR-T Cells exhibit potent antitumor activity in β6-Positive pancreatic ductal adenocarcinoma and lung adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) remain lethal malignancies with limited therapeutic options, highlighting an urgent need for more effective treatments. Integrin αvβ6 (ITGB6) is a receptor preferentially expressed in specific types of tumors, such as PDAC and LUAD, and represents a promising yet largely untapped target for cellular immunotherapy. We aimed to develop and preclinically validate a novel chimeric antigen receptor T-cell (CAR-T) therapy targeting ITGB6 for these aggressive solid tumors. A third-generation anti-ITGB6 CAR was designed and constructed, incorporating both CD28 and TLR2 co-stimulatory domains. TLR2 signaling enhances T-cell expansion, cytokine production, and infiltration into solid tumor. The potency and specificity of anti-ITGB6 CAR-T cells were assessed against a panel of ITGB6-positive PDAC and LUAD cell lines, patient-derived organoids (PDOs), orthotopic models, and patient-derived xenograft (PDX) models. Anti-ITGB6 CAR-T cells demonstrated potent cytotoxicity against ITGB6-positive PDAC and LUAD models in vitro, effectively targeting both cell lines and PDOs. In murine xenograft models, a single dose of anti-ITGB6 CAR-T cells induced significant tumor suppression and prolonged survival, with no evidence of on-target/off-tumor toxicity was observed. Our findings provide compelling preclinical proof-of-concept for anti-ITGB6 CAR-T therapy as a potent and safe investigational strategy against ITGB6-positive solid tumors, supporting its clinical translation for patients with PDAC and LUAD.
- Open Access
The S1 B -Targeting PEDV Neutralizing Antibody C62 Prematurely Activates S-trimer and Mimics Receptor Function
Porcine epidemic diarrhea virus (PEDV) causes devastating enteric disease in piglets, yet the mechanistic basis of antibody-mediated neutralization remains poorly understood. Here, we determined the structure of PEDV HNXX-strain spike domain B (S1 B ) simultaneously bound by C62, a neutralizing porcine monoclonal antibody against PEDV G2 strains, and N34, a non-neutralizing porcine PEDV antibody. The structure reveals that C62 targets a conserved, cryptic epitope that is accessible only when S1 B adopts an “up” conformation. Functionally, we showed that C62 has substantially stronger activity than N34 in triggering S-trimer disassembly and inducing the formation of proteinase K-resistant, post-fusion-like S2 structures. Despite the weaker triggering activity of N34, both C62 and N34 can function as artificial receptors. Notably, although the C62 epitope is conserved across both G1 and G2 strains, C62 exhibits G2-strain-biased neutralizing activity. We further showed that differences in cell-surface membrane fusion activity among PEDV spikes correlate with distinct viral entry pathways and are jointly determined by the S1 A and S1 B sequences. Together, our findings identify a strain-specific vulnerable site on the PEDV S-trimer and provide insight into how cell-surface membrane fusion activity may influence viral entry pathway selection and antibody neutralization efficacy.
Open AccessThe S1 B -Targeting PEDV Neutralizing Antibody C62 Prematurely Activates S-trimer and Mimics Receptor Function
Porcine epidemic diarrhea virus (PEDV) causes devastating enteric disease in piglets, yet the mechanistic basis of antibody-mediated neutralization remains poorly understood. Here, we determined the structure of PEDV HNXX-strain spike domain B (S1 B ) simultaneously bound by C62, a neutralizing porcine monoclonal antibody against PEDV G2 strains, and N34, a non-neutralizing porcine PEDV antibody. The structure reveals that C62 targets a conserved, cryptic epitope that is accessible only when S1 B adopts an “up” conformation. Functionally, we showed that C62 has substantially stronger activity than N34 in triggering S-trimer disassembly and inducing the formation of proteinase K-resistant, post-fusion-like S2 structures. Despite the weaker triggering activity of N34, both C62 and N34 can function as artificial receptors. Notably, although the C62 epitope is conserved across both G1 and G2 strains, C62 exhibits G2-strain-biased neutralizing activity. We further showed that differences in cell-surface membrane fusion activity among PEDV spikes correlate with distinct viral entry pathways and are jointly determined by the S1 A and S1 B sequences. Together, our findings identify a strain-specific vulnerable site on the PEDV S-trimer and provide insight into how cell-surface membrane fusion activity may influence viral entry pathway selection and antibody neutralization efficacy.
- 22 July 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1073-1083
Structures and inhibition of the Crimean–Congo haemorrhagic fever virus polymerase
- 22 July 2026
- Published by Springer Nature in Nature
- Vol. 657 (8133) , 1073-1083
Structures and inhibition of the Crimean–Congo haemorrhagic fever virus polymerase
- Open Access
- 5 May 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (9)
Chromatin context-dependent deacetylation by the asymmetric Rpd3L
The regulation of gene expression requires precise control of chromatin-associated complexes that respond to diverse structural and epigenetic cues. The Rpd3 Large (Rpd3L) complex is a Sin3 histone deacetylase complex (HDAC) that dynamically adapt to chromatin states to reinforce transcriptional silencing, yet the mechanisms governing the catalytic activation in chromatin context-dependent manner remain unclear. Here we present the cryo-electron microscopy structure of Rpd3L bound to both mono- and di-nucleosome substrate at near-atomic resolution, uncovering a substrate-guided allosteric activation mechanism. Rpd3L adopts an asymmetric architecture, in which the proximal catalytic module anchors the first nucleosome, while the Sin3 PAH domains engage linker DNA to reposition a second nucleosome. This spatial configuration brings the distal catalytic module into proximity with chromatin and unlocks its latent deacetylase activity. Biochemical and mass spectrometry analyses confirm that dual nucleosome engagement selectively enhances Rpd3L activity and broadens substrate specificity. Together, these findings establish a hierarchical mechanism by which Rpd3L interprets histone modifications and nucleosome organization to modulate its enzymatic output at promoter regions. Our study provides a framework for understanding higher-order chromatin repression mechanisms by chromatin-regulation complexes and co-repressors.
- 5 May 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (9)
Open AccessChromatin context-dependent deacetylation by the asymmetric Rpd3L
The regulation of gene expression requires precise control of chromatin-associated complexes that respond to diverse structural and epigenetic cues. The Rpd3 Large (Rpd3L) complex is a Sin3 histone deacetylase complex (HDAC) that dynamically adapt to chromatin states to reinforce transcriptional silencing, yet the mechanisms governing the catalytic activation in chromatin context-dependent manner remain unclear. Here we present the cryo-electron microscopy structure of Rpd3L bound to both mono- and di-nucleosome substrate at near-atomic resolution, uncovering a substrate-guided allosteric activation mechanism. Rpd3L adopts an asymmetric architecture, in which the proximal catalytic module anchors the first nucleosome, while the Sin3 PAH domains engage linker DNA to reposition a second nucleosome. This spatial configuration brings the distal catalytic module into proximity with chromatin and unlocks its latent deacetylase activity. Biochemical and mass spectrometry analyses confirm that dual nucleosome engagement selectively enhances Rpd3L activity and broadens substrate specificity. Together, these findings establish a hierarchical mechanism by which Rpd3L interprets histone modifications and nucleosome organization to modulate its enzymatic output at promoter regions. Our study provides a framework for understanding higher-order chromatin repression mechanisms by chromatin-regulation complexes and co-repressors.
- Open Access
- 20 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Functional and structural basis of a negative allostery within GABAB hetero-tetramers
G protein coupled receptors (GPCRs) oligomerization may allow signal integration from different GPCR units. The GABAB receptor, activated by the main inhibitory transmitter, GABA, is an obligatory heterodimer. It is the target of two therapeutic drugs, baclofen and GHB, and can form stable oligomers. The existence, roles, and possible allosteric interaction of GABAB oligomers remain elusive. Here, we show that GABAB oligomers exist in neurons. Their function can be specifically affected by human disease-associated mutations, demonstrating their essential role for normal brain function. The cryo-EM structure of a hetero-tetramer in the apo state reveals the heterodimers interacting in an asymmetrical way to prevent one unit from being activated. This represents a nice example of a negative allosteric interaction between GPCRs related to human diseases.
- 20 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessFunctional and structural basis of a negative allostery within GABAB hetero-tetramers
G protein coupled receptors (GPCRs) oligomerization may allow signal integration from different GPCR units. The GABAB receptor, activated by the main inhibitory transmitter, GABA, is an obligatory heterodimer. It is the target of two therapeutic drugs, baclofen and GHB, and can form stable oligomers. The existence, roles, and possible allosteric interaction of GABAB oligomers remain elusive. Here, we show that GABAB oligomers exist in neurons. Their function can be specifically affected by human disease-associated mutations, demonstrating their essential role for normal brain function. The cryo-EM structure of a hetero-tetramer in the apo state reveals the heterodimers interacting in an asymmetrical way to prevent one unit from being activated. This represents a nice example of a negative allosteric interaction between GPCRs related to human diseases.
- Open Access
- 5 February 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (4)
Structural basis for BCL7B-mediated ncBAF-nucleosome engagement
The mammalian SWI/SNF family of chromatin remodelers comprises BRG1/BRM-associated factor (cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF) complexes, which slide and disassemble nucleosomes to regulate gene expression and chromatin structure dependent on ATP hydrolysis energy. While the chromatin engagement mechanisms of cBAF and PBAF have been structurally resolved, the molecular architecture governing ncBAF interaction with chromatin remains elusive. In this study, by integrating cryo-electron microscopy, biochemical assays, and cross-linking mass spectrometry, we resolved the conformational transition of ncBAF-nucleosome complexes from nucleotide-free to nucleotide-bound states. Our analyses establish BCL7 proteins as dynamic molecular tethers connecting the ARP module to the nucleosomal acidic patch and demonstrate that BCL7B promotes ncBAF-mediated nucleosome remodeling, with BRG1-catalyzed ATP hydrolysis triggering conformational changes that modulate BCL7-mediated histone association. Structurally and biochemically, we further demonstrate that β-actin within the BCL7-containing ARP module retains ATP hydrolysis activity, rendering its exposed pointed end structurally compatible with incorporation into the barbed end of nuclear actin filaments, which provides a potential molecular basis for coordinating nuclear actin networks with chromatin remodeling. Collectively, our findings unravel a dynamic role of BCL7 in regulating ncBAF-mediated chromatin remodeling and establish a distinct chromatin engagement mode of ncBAF from that of cBAF/PBAF.
- 5 February 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (4)
Open AccessStructural basis for BCL7B-mediated ncBAF-nucleosome engagement
The mammalian SWI/SNF family of chromatin remodelers comprises BRG1/BRM-associated factor (cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF) complexes, which slide and disassemble nucleosomes to regulate gene expression and chromatin structure dependent on ATP hydrolysis energy. While the chromatin engagement mechanisms of cBAF and PBAF have been structurally resolved, the molecular architecture governing ncBAF interaction with chromatin remains elusive. In this study, by integrating cryo-electron microscopy, biochemical assays, and cross-linking mass spectrometry, we resolved the conformational transition of ncBAF-nucleosome complexes from nucleotide-free to nucleotide-bound states. Our analyses establish BCL7 proteins as dynamic molecular tethers connecting the ARP module to the nucleosomal acidic patch and demonstrate that BCL7B promotes ncBAF-mediated nucleosome remodeling, with BRG1-catalyzed ATP hydrolysis triggering conformational changes that modulate BCL7-mediated histone association. Structurally and biochemically, we further demonstrate that β-actin within the BCL7-containing ARP module retains ATP hydrolysis activity, rendering its exposed pointed end structurally compatible with incorporation into the barbed end of nuclear actin filaments, which provides a potential molecular basis for coordinating nuclear actin networks with chromatin remodeling. Collectively, our findings unravel a dynamic role of BCL7 in regulating ncBAF-mediated chromatin remodeling and establish a distinct chromatin engagement mode of ncBAF from that of cBAF/PBAF.
- Open Access
Chromatin context-dependent deacetylation by the asymmetric Rpd3L
The regulation of gene expression requires precise control of chromatin-associated complexes that respond to diverse structural and epigenetic cues. The Rpd3 Large (Rpd3L) complex is a Sin3 histone deacetylase (HDAC) complex that dynamically adapt to chromatin states to reinforce transcriptional silencing, yet the mechanisms governing the catalytic activation in chromatin context-dependent manner remain unclear. Here we present the cryo-EM structure of Rpd3L bound to both mono- and di-nucleosome substrate at near-atomic resolution, uncovering a substrate-guided allosteric activation mechanism. Rpd3L adopts an asymmetric architecture, in which the proximal catalytic module anchors the first nucleosome, while the Sin3 PAH domains engage linker DNA to reposition a second nucleosome. This spatial configuration brings the distal catalytic module into proximity with chromatin and unlocks its latent deacetylase activity. Biochemical and mass spectrometry analyses confirm that dual nucleosome engagement selectively enhances Rpd3L activity and broadens substrate specificity. Together, these findings establish a hierarchical mechanism by which Rpd3L interprets histone modifications and nucleosome organization to modulate its enzymatic output at promoter regions. Our study provides a framework for understanding higher-order chromatin repression mechanisms by chromatin-regulation complexes and co-repressors.
Open AccessChromatin context-dependent deacetylation by the asymmetric Rpd3L
The regulation of gene expression requires precise control of chromatin-associated complexes that respond to diverse structural and epigenetic cues. The Rpd3 Large (Rpd3L) complex is a Sin3 histone deacetylase (HDAC) complex that dynamically adapt to chromatin states to reinforce transcriptional silencing, yet the mechanisms governing the catalytic activation in chromatin context-dependent manner remain unclear. Here we present the cryo-EM structure of Rpd3L bound to both mono- and di-nucleosome substrate at near-atomic resolution, uncovering a substrate-guided allosteric activation mechanism. Rpd3L adopts an asymmetric architecture, in which the proximal catalytic module anchors the first nucleosome, while the Sin3 PAH domains engage linker DNA to reposition a second nucleosome. This spatial configuration brings the distal catalytic module into proximity with chromatin and unlocks its latent deacetylase activity. Biochemical and mass spectrometry analyses confirm that dual nucleosome engagement selectively enhances Rpd3L activity and broadens substrate specificity. Together, these findings establish a hierarchical mechanism by which Rpd3L interprets histone modifications and nucleosome organization to modulate its enzymatic output at promoter regions. Our study provides a framework for understanding higher-order chromatin repression mechanisms by chromatin-regulation complexes and co-repressors.